Biolase (BIOL) Tops Q2 EPS by 4c

Biolase (NASDAQ: BIOL) reported Q2 EPS of $0.00, $0.04 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $9.1 million versus the consensus estimate of $8.31 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Baker Hughes Company (BKR) Tops Q1 EPS by 4c, Beats on Revenue
• Highwoods Properties (HIW) Tops Q1 EPS by 6c, provides guidance